相似文献
1
Macrolide resistance in pneumococci-is it relevant?
Pneumonia (Nathan). 2016 Jul 7;8:10. doi: 10.1186/s41479-016-0010-1. eCollection 2016.
2
What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
Infect Dis Clin North Am. 2013 Mar;27(1):87-97. doi: 10.1016/j.idc.2012.11.013.
3
Macrolide Resistance in .
Front Cell Infect Microbiol. 2016 Sep 21;6:98. doi: 10.3389/fcimb.2016.00098. eCollection 2016.
4
Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
Clin Infect Dis. 2002 Mar 1;34 Suppl 1:S27-46. doi: 10.1086/324527.
5
Mechanism of Macrolide-Induced Inhibition of Pneumolysin Release Involves Impairment of Autolysin Release in Macrolide-Resistant Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00161-18. Print 2018 Nov.
6
Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
Clin Infect Dis. 2004 May 15;38 Suppl 4:S346-9. doi: 10.1086/382691.
7
Macrolide resistance among invasive Streptococcus pneumoniae isolates.
JAMA. 2001 Oct 17;286(15):1857-62. doi: 10.1001/jama.286.15.1857.
8
Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
J Lab Clin Med. 2004 May;143(5):269-83. doi: 10.1016/j.lab.2004.02.002.
9
Pneumococcal macrolide resistance--myth or reality?
J Antimicrob Chemother. 1999 Jul;44(1):1-6. doi: 10.1093/jac/44.1.1.
10
Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents.
Clin Infect Dis. 2001 Aug 15;33(4):483-8. doi: 10.1086/322735. Epub 2001 Jul 20.
引用本文的文献
1
Characterization of MultidrugResistant serogroup 19 isolated from healthy children below 5 years of age in Indonesia.
Access Microbiol. 2024 Feb 13;6(2). doi: 10.1099/acmi.0.000680.v4. eCollection 2024.
2
Serotype Distribution and Multi Locus Sequence Type (MLST) of Erythromycin-Resistant Isolates in Tehran, Iran.
Rep Biochem Mol Biol. 2023 Jul;12(2):259-268. doi: 10.61186/rbmb.12.2.259.
3
Global Distribution and Diversity of Prevalent Sewage Water Plasmidomes.
mSystems. 2022 Oct 26;7(5):e0019122. doi: 10.1128/msystems.00191-22. Epub 2022 Sep 7.
4
Increase of Macrolide-Resistance in Strains After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Lima, Peru.
Front Cell Infect Microbiol. 2022 May 9;12:866186. doi: 10.3389/fcimb.2022.866186. eCollection 2022.
5
Phenotypic and Molecular Characterization of Penicillin and Macrolide-Resistant Serotypes Among Pediatric Patients in Addis Ababa, Ethiopia.
Infect Drug Resist. 2021 May 12;14:1765-1772. doi: 10.2147/IDR.S309876. eCollection 2021.
6
Nursing Home-Associated Pneumonia, Part II: Etiology and Treatment.
J Am Med Dir Assoc. 2020 Mar;21(3):315-321. doi: 10.1016/j.jamda.2020.01.012. Epub 2020 Feb 13.
7
Real-world safety evaluation of musculoskeletal adverse events associated with Korean pediatric fluoroquinolone use: a nationwide longitudinal retrospective cohort study.
Sci Rep. 2019 Dec 27;9(1):20156. doi: 10.1038/s41598-019-56815-y.
8
Deciphering the distance to antibiotic resistance for the pneumococcus using genome sequencing data.
Sci Rep. 2017 Feb 16;7:42808. doi: 10.1038/srep42808.
本文引用的文献
1
Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany.
Int J Med Microbiol. 2015 Oct;305(7):776-83. doi: 10.1016/j.ijmm.2015.08.031. Epub 2015 Aug 22.
2
Antibiotic treatment strategies for community-acquired pneumonia in adults.
N Engl J Med. 2015 Apr 2;372(14):1312-23. doi: 10.1056/NEJMoa1406330.
3
The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia.
Am J Respir Crit Care Med. 2015 Jun 1;191(11):1265-72. doi: 10.1164/rccm.201502-0212OC.
4
Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae.
J Infect Dis. 2015 Apr 1;211(7):1144-53. doi: 10.1093/infdis/jiu576. Epub 2014 Oct 29.
5
Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments.
J Infect Dis. 2015 Mar 15;211(6):988-94. doi: 10.1093/infdis/jiu552. Epub 2014 Oct 6.
6
β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
JAMA Intern Med. 2014 Dec;174(12):1894-901. doi: 10.1001/jamainternmed.2014.4887.
7
Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013.
Emerg Infect Dis. 2014 Jul;20(7):1132-9. doi: 10.3201/eid2007.131485.
8
Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
J Antimicrob Chemother. 2014 Oct;69(10):2835-40. doi: 10.1093/jac/dku207. Epub 2014 Jun 11.
9
Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010.
Antimicrob Agents Chemother. 2014 May;58(5):2763-6. doi: 10.1128/AAC.02239-13. Epub 2014 Mar 3.
10
β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis.
J Antimicrob Chemother. 2014 Jun;69(6):1441-6. doi: 10.1093/jac/dku033. Epub 2014 Feb 16.
Zotero 插件